A focused mastery of inhibitory pathways for therapeutic targeting

The inhibitory receptor landscape is key to understanding immune regulation and yet is largely unexplored. MiroBio has created the I-ReSToRE platform to systematically assess these receptors’ roles in immunity and their potential as therapeutic targets for immune-mediated disease.  I-ReSToRE builds on 15 years of foundational research with a wide array of cutting-edge techniques for discovery and candidate creation. Our work has generated a broad pipeline of inhibitory receptor agonists focused on targets with the greatest potential in autoimmunity.

The I-ReSToRE platform uses deep
analytics to paint a picture of autoimmunity
with industry-leading clarity

I-ReSToRE is designed to produce the highest-resolution map of inhibitory signalling in the industry. We leverage our scientific expertise to understand these networks – from the genetics to the symptoms that patients experience.

Working with vast data sets and material from our clinical collaborators, we continually bring a clearer picture of inhibitory signalling networks and the potential for therapeutic intervention into focus. This process is both broad in scope and deep in its analyses. The result is the ability to identify novel drug targets and generate optimized drug candidates for them.

I-ReSToRE comprehensively assesses:



The changes in receptor and gene expression as well as receptor signaling activity that occurs across immune cell types in immune-mediated diseases



How these changes affect in vitro and in vivo models of increasing complexity in healthy versus diseased states


The available capacity for modulation (‘inhibitory reserve’) in pathways of interest


The specific type of inhibitory receptor signaling with the greatest therapeutic potential in various patient populations

Knowledge catalyzed into candidates:
Checkpoint agonist antibodies

MiroBio’s checkpoint agonist antibodies are designed to restore immune balance and treat autoimmune disease. We have developed a proprietary Checkpoint Atlas™ of receptor expression and function; based on a deep understanding of the mechanisms of receptor triggering, our antibodies are uniquely designed to optimally agonize specific immune receptors. We have broad antibody engineering capabilities across traditional and novel approaches – the focus is the best molecule for the need.

Signalling know-how: Modulating the
immune synapse to enhance potency

MiroBio draws from a deep knowledge of inhibitory receptor signalling detailed in the Checkpoint Atlas™ to maximize the potency of its therapeutics. For example, we can influence this signalling by manipulating features of the immune synapse, which is a gap that forms between two cells to allow crucial interactions.

Our antibodies are designed to optimize the immune synapse to generate an artificial signal through the immune receptor. For some receptors, we can perpetuate these signals through antibodies designed to enforce a very narrow immune synapse. This restricted space prevents the entry of enzymes that would normally halt signalling.

If advantageous, MiroBio’s antibodies can even allow binding between the receptor and its native ligand, giving us greater control over the relevant signalling pathways.

A pipeline focused on the most
impactful inhibitory receptors for
autoimmune disease

MiroBio identifies a target according to its breadth of involvement in autoimmune and other immune-mediated diseases with high unmet need. Targets are also prioritized based on the degree to which their pathways have room for modulation, or their inhibitory reserve. Finally, MiroBio seeks targets where our scientific leadership can yield first-in-class or superior candidates.

The complex nature of autoimmune diseases, their rising prevalence and the clear limitations of current standards of care create major opportunities for MiroBio’s precision approach.

MiroBio’s most advanced candidate in development is an agonist of BTLA (B- and T-lymphocyte attenuator). BTLA’s ability to modulate both B- and T-cells gives it a far-reaching regulatory effect and versatility as a target across several major autoimmune diseases.

MB272: BTLA Agonist
MB151: PD-1 Agonist
Multiple early-stage assets
Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser